Updates to NeoOPTIMIZE: an Open-Label, Phase II Trial and Biomarker Discovery Platform to Assess the Efficacy of Adaptive Switching of Modified FOLFIRINOX (mffx) or Gemcitabine/ Nab-Paclitaxel (GA) As a Neoadjuvant Strategy for Patients with Resectable/borderline Resectable and Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma (PDAC).